• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Arrowhead Pharma (NQ: ARWR )

    21.39 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Arrowhead Pharma

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Arrowhead Pharmaceuticals's Return On Capital Employed Insights
    According to data from Benzinga Pro, during Q1, Arrowhead Pharmaceuticals's (NASDAQ:ARWR) reported sales totaled $27.44 million. Despite a 0.79% increase in earnings, the company posted a loss of... 
    Via Benzinga
    The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Recap: Arrowhead Pharmaceuticals Q1 Earnings
      Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q1 earnings results on Wednesday, February 2, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
    Here's a roundup of top developments in the biotech space over the last 24 hours. 
    Via Benzinga
    The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
    The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
    Via Benzinga
    Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Earnings Scheduled For February 2, 2022
    Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is likely to report quarterly earnings at $1.57 per share on revenue of $24.59 billion. 
    Via Benzinga
    Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022
    Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo... 
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
    This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
    Via Benzinga
    Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In... 
    Via Benzinga
    Exposures COVID-19 Product Safety
    GlaxoSmithKline Pens $1B Pact For NASH Candidate With Arrowhead
    Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) entered a drug development deal with GlaxoSmithKline Plc (NYSE: GSK), under which GSK will develop and market... 
    Via Benzinga
    4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout
    The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer. 
    Via The Motley Fool
    Arrowhead Pharmaceuticals, inc (ARWR) Q4 2021 Earnings Call Transcript
    ARWR earnings call for the period ending September 30, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022
    Alnylam is working on a drug that could tackle transthyretin cardiomyopathy. 
    Via Investor's Business Daily
    Earnings Scheduled For November 22, 2021
    Companies Reporting Before The Bell • Cerence (NASDAQ:CRNC) is estimated to report quarterly earnings at $0.56 per share on revenue of $97.92 million. • Avaya... 
    Via Benzinga
    The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
    Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting... 
    Via Talk Markets
    Exposures Product Safety
    The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
    Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the... 
    Via Benzinga
    Exposures Product Safety
    Earnings Outlook For Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals (NASDAQ:ARWR) is set to give its latest quarterly earnings report on Monday, 2021-11-22. Here's what investors need to know before the announcement.... 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA) shares moved upwards by 78.87% to $38.06 during Thursday's regular session. As of 12:30 EST, this security is trading at... 
    Via Benzinga
    Arrowhead Announces JNJ-75220795 in Development for NASH
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.